$IMRX
Immuneering Corp
Nasdaq · Healthcare · Pharmaceutical Preparations · Cambridge, MA
IMRX chart
What traders are saying about $IMRX
Latest postsImmuneering Corp news
- Immuneering Corporation (IMRX) stock price, news, quote and history
Yahoo Finance UK ·
- Immuneering presents phase 3 pancreatic cancer trial design
Investing.com ·
- Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Yahoo Finance ·
- Immuneering Corporation Estimates – NASDAQ:IMRX
TradingView ·
- What Separates Immuneering (NASDAQ:IMRX), Pharvaris (NASDAQ:PHVS) and Veraxa Biotech (NASDAQ:VRXA) as Biotechs Rise Premarket?
kalkine.ca ·
- Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Yahoo Finance ·
- Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Yahoo Finance ·
- Immuneering to Present at the ESMO Congress 2026
Yahoo Finance ·
- Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Yahoo Finance ·
- Immuneering to Participate in Upcoming Investor Conferences
Yahoo Finance ·
- Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Yahoo Finance ·
- Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
Yahoo Finance ·
Immuneering Corp key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $0 | $316,952 |
| Net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M |
| Diluted EPS | $-1.27 | $-2.04 | $-1.88 | $-1.91 |
| Total assets (year end) | $232.0M | $52.7M | $102.6M | $122.4M |
| Cash and equivalents (year end) | $128.6M | $36.1M | $59.4M | $72.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Immuneering Corp
- Ticker
- IMRX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1790340
Frequently asked questions
What exchange is Immuneering Corp listed on?
Immuneering Corp trades on the Nasdaq under the ticker symbol IMRX.
What industry is Immuneering Corp in?
Immuneering Corp is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Immuneering Corp headquartered?
Immuneering Corp's business address on file with the SEC is in Cambridge, MA.
When does Immuneering Corp's fiscal year end?
Immuneering Corp's fiscal year ends on December 31.
How much revenue did Immuneering Corp report?
Immuneering Corp reported $0 in revenue for calendar year 2023, according to its SEC filings.